In order to serve the market in Africa, BioNTech will erect a 300,000 square foot production facility in Kigali, Rwanda.  The plant will produce experimental mRNA-based vaccines against malaria and tuberculosis and for COVID, all subject to governmental approval.

BioNTech will provide turnkey production modules to be delivered during the second half of 2022 with production scheduled in 2023.  It is projected that 50 million doses of COVID vaccine will be produced annually.  The mRNA malaria and tuberculosis vaccines will be initially evaluated in human trials.  Currently, Africa produces only one percent of vaccine requirement and the BioNTech plant will contribute to self-sufficiency.